|
“Arresto:
Blocking
fibroblasts”
Emerging Company Profile featured in the June 28, 2010 issue of BioCentury.
 PDF Download
Arresto BioSciences™ recently
published a novel drug strategy that combines the advantages of
allosteric modulators of enzymatic function with the specificity,
selectivity, and pharmacologic properties of antibodies. Arresto
BioSciences™ is using this approach to develop novel therapeutics
for
treating conditions such as oncology, fibrosis and inflammation.
Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric
antibody inhibitor
Hector M. Rodriguez, Maria Vaysberg, Amanda Mikels, Scott McCauley,
Arleene C. Velayo, Carlos Garcia and Victoria Smith
The Journal of Biological Chemistry, in press. Published on May 3, 2010.
http://www.jbc.org/cgi/doi/10.1074/jbc.M109.094136
|
